The primary hyperoxaluria treatment market share is anticipated to reach a valuation of US$ 18 million globally in 2023, and it is anticipated to grow at a compound annual growth rate (CAGR) of 8.6% to reach US$ 41.07 million during the forecast period of 2023 to 2033. Historically, the market for primary hyperoxaluria treatment grew at a compound annual growth rate (CAGR) of 5.2% from 2018 to...